British Journal of Dermatology

Cover image for Vol. 170 Issue 3

March 2014

Volume 170, Issue 3

Pages i–i, 485–758, e1–e13

  1. Editor's Choice

    1. Top of page
    2. Editor's Choice
    3. Editorials
    4. Commentaries
    5. Putting papers into practice
    6. Review articles
    7. Meeting report
    8. Original articles
    9. Correspondence
    10. News and Notices
    11. Plain language summary
    12. Abstract
  2. Editorials

    1. Top of page
    2. Editor's Choice
    3. Editorials
    4. Commentaries
    5. Putting papers into practice
    6. Review articles
    7. Meeting report
    8. Original articles
    9. Correspondence
    10. News and Notices
    11. Plain language summary
    12. Abstract
  3. Commentaries

    1. Top of page
    2. Editor's Choice
    3. Editorials
    4. Commentaries
    5. Putting papers into practice
    6. Review articles
    7. Meeting report
    8. Original articles
    9. Correspondence
    10. News and Notices
    11. Plain language summary
    12. Abstract
    1. Nitrogen mustard revisited (page 495)

      R. Knobler

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12890

      ORIGINAL ARTICLE, p 699

  4. Putting papers into practice

    1. Top of page
    2. Editor's Choice
    3. Editorials
    4. Commentaries
    5. Putting papers into practice
    6. Review articles
    7. Meeting report
    8. Original articles
    9. Correspondence
    10. News and Notices
    11. Plain language summary
    12. Abstract
  5. Review articles

    1. Top of page
    2. Editor's Choice
    3. Editorials
    4. Commentaries
    5. Putting papers into practice
    6. Review articles
    7. Meeting report
    8. Original articles
    9. Correspondence
    10. News and Notices
    11. Plain language summary
    12. Abstract
    1. Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research (pages 501–513)

      F.M. Garritsen, M.W.D. Brouwer, J. Limpens and Ph. I. Spuls

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12645

      • image
      • image
      • image
      • image

      What's already known about this topic?

      • Reviews on photo(chemo)therapy in atopic dermatitis (AD) are dated and need to be performed more accurately and systematically.

      What does this study add?

      • This is the first systematic review on photo(chemo)therapy using Grading of Recommendations Assessment, Development and Evaluation (GRADE) to provide a comprehensive quality assessment of the included evidence, on which conclusions may be drawn and recommendations for daily practice can be based.
      • Our results strengthen the existing guidelines on AD; preference is given to ultraviolet (UV) A1 and narrowband-UVB.
    2. Dermoscopy in general dermatology: practical tips for the clinician (pages 514–526)

      A. Lallas, J. Giacomel, G. Argenziano, B. García-García, D. González-Fernández, I. Zalaudek and F. Vázquez-López

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12685

      • image
      • image
      • image
      • image
      • image
      • image
      • image
      • image
      • image
      • image
      • image

      What's already known about this topic?

      • Dermoscopy has well-documented value in improving the diagnosis of skin tumours.
      • It is continually gaining appreciation in the field of general dermatology.

      What does this study add?

      • We provide a succinct summary of existing data on dermoscopy in general dermatology.
      • Practical tips are suggested, which can assist clinicians in profitably utilizing and applying the available knowledge in their everyday practice.
    3. Striae distensae: a comprehensive review and evidence-based evaluation of prophylaxis and treatment (pages 527–547)

      S. Al-Himdani, S. Ud-Din, S. Gilmore and A. Bayat

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12681

      • image
      • image
      • image

      What's already known about this topic?

      • Striae distensae are extremely common and pose a significant psychological burden for patients.
      • They commonly occur during pregnancy and adolescence.
      • Topical, laser and light therapies can be used as treatment.

      What does this study add?

      • We provide an up-to-date review of the literature regarding striae distensae, their epidemiology, histopathology and assessment.
      • We also provide an evidence-based evaluation of topical, laser and light therapies used to treat striae distensae.
    4. You have free access to this content
      How are eczema ‘flares’ defined? A systematic review and recommendation for future studies (pages 548–556)

      S.M. Langan, J. Schmitt, H.C. Williams, S. Smith and K.S. Thomas

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12747

      • image
      • image

      What's already known about this topic?

      • As a chronic, relapsing disease, the ability to capture disease flares is important when evaluating treatment success, yet it is unclear how flares should be defined.
      • The international Harmonising Outcome Measure for Eczema (HOME) initiative has reached consensus that ‘long-term control’ should be captured in all future eczema trials, but how this should be done is unclear.

      What does this study add?

      • There has been a steady increase in the use of flare outcomes in eczema clinical trials.
      • This review highlights the wide variation in flare definitions currently in use and the complete lack of validation of those definitions. Such variation hampers comparison of findings between different studies, and limits the clinical interpretation of trial evidence.
      • This review highlights some of the key methodological difficulties in applying flare definitions in clinical trials.
    5. Systematic review on the rapidity of the onset of action of topical treatments in the therapy of mild-to-moderate acne vulgaris (pages 557–564)

      A. Jacobs, G. Starke, S. Rosumeck and A. Nast

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12706

      • image
      • image
      • image

      What's already known about this topic?

      • The efficacy of most topical acne treatments is comparable; however, assessments of the time until the onset of action of acne treatments are rare.
      • Patients with acne often experience a negative influence on their psychological well-being as well as on their quality of life.

      What does this study add?

      • Higher concentrations of commonly used acne treatments do not seem to lead to a faster onset of action than the respective lower concentrations.
      • Adapalene has a faster onset of action than isotretinoin.
      • The combination treatments clindamycin/benzoyl peroxide (BPO) and adapalene/BPO show comparable times until onset of action.
  6. Meeting report

    1. Top of page
    2. Editor's Choice
    3. Editorials
    4. Commentaries
    5. Putting papers into practice
    6. Review articles
    7. Meeting report
    8. Original articles
    9. Correspondence
    10. News and Notices
    11. Plain language summary
    12. Abstract
    1. You have free access to this content
  7. Original articles

    1. Top of page
    2. Editor's Choice
    3. Editorials
    4. Commentaries
    5. Putting papers into practice
    6. Review articles
    7. Meeting report
    8. Original articles
    9. Correspondence
    10. News and Notices
    11. Plain language summary
    12. Abstract
    1. Cutaneous biology

      You have free access to this content
      The effect of adalimumab on key drivers in the pathogenesis of psoriasis (pages 571–580)

      A.G.M. Hendriks, H.M.J. van der Velden, E.A.W. Wolberink, M.M.B. Seyger, J. Schalkwijk, P.L.J.M. Zeeuwen, E.M.G.J. de Jong, M.C. Pasch, P.E.J. van Erp and P.C.M. van de Kerkhof

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12705

      • image
      • image
      • image
      • image
      • image

      What's already known about this topic?

      • Recently introduced biologics targeting specific immune mechanisms have identified crucial steps in the pathogenesis of psoriasis.

      What does this study add?

      • During adalimumab treatment markers of epidermal differentiation, proliferation and the innate immune system revert rapidly to normal, well before changes in the adaptive immune system become apparent.
    2. Four compartment method: a simplified and cost-effective method of noncultured epidermal cell suspension for the treatment of vitiligo (pages 581–585)

      R. Kumar, D. Parsad, C. Singh and S. Yadav

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12725

      • image
      • image
      • image

      What's already known about this topic?

      • In surgical methods, transplantation of noncultured epidermal cell suspension (NCECS) is emerging as the treatment of choice for stable vitiligo.
      • Existing methods for preparation of NCECS are cumbersome and expensive. They involve creation of laboratory facilities and the need for research laboratory equipment such as a centrifuge and laminar flow.

      What does this study add?

      • We simplified the existing method and developed a new simple method, named the four compartment (FC) method, for the preparation of NCECS.
      • This method overcomes the limitations of needing laboratory facilities and equipment, and enables harvesting of the cells in a very easy manner.
      • This new FC method enables widespread use of the technique of NCECS for the treatment of vitiligo in an easy and cost-effective manner.
    3. Clinical and laboratory investigations

      Type 2A Koebner phenomenon in vitiligo is distinct from other subtypes: observations from an Indian cohort (pages 586–590)

      A.J. Kanwar, R. Mahajan and D. Parsad

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12651

      What's already known about this topic?

      • Koebner phenomenon (KP) is classified as type 1, 2A or 2B on the basis of history and examination.

      What does this study add?

      • Patients manifesting KP have a higher mean age, age at onset and total body surface area involvement, and a significantly higher chance of being administered oral corticosteroids to arrest disease activity.
      • Type 2A KP is significantly different from other subtypes of KP.
      • Type 1 and type 2B KP are more similar to each other than they are to the other types.
    4. Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes (pages 591–598)

      M. Augustin, C. Blome, A. Costanzo, E. Dauden, C. Ferrandiz, G. Girolomoni, R. Gniadecki, L. Iversen, A. Menter, K. Michaelis-Wittern, A. Morita, H. Nakagawa and K. Reich

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12664

      • image

      What's already known about this topic?

      • Existing tools for assessment of nail psoriasis are complex and may not adequately measure outcomes that are important to patients.

      What does this study add?

      • We developed and validated a new tool, the Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA), which assesses quality of life (NAPPA-QoL), patient-relevant treatment benefits (NAPPA-PBI) and nail psoriasis severity (NAPPA-CLIN).
      • The NAPPA tool is valid, reliable and practical for use in clinical and research settings to assess patient-relevant nail psoriasis outcomes.
    5. What are the supportive and palliative care needs of patients with cutaneous T-cell lymphoma and their caregivers? A systematic review of the evidence (pages 599–608)

      T. Beynon, E. Radcliffe, F. Child, D. Orlowska, S. Whittaker, S. Lawson, L. Selman and R. Harding

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12644

      • image

      What's already known about this topic?

      • Cutaneous T-cell lymphoma (CTCL) has significant symptoms and sometimes a poor prognosis.
      • Palliative care can improve symptom management, communication and satisfaction of patients and caregivers in progressive disease.

      What does this study add?

      • No outcome measure routinely reports quality-of-life, supportive or palliative care needs or outcomes for CTCL.
      • There is some evidence that the high symptom and emotional burden of patients with CTCL improves with systemic treatment.
      • There are no data available on the needs of caregivers of patients with CTCL.
    6. Increased number and frequency of group 3 innate lymphoid cells in nonlesional psoriatic skin (pages 609–616)

      B. Dyring-Andersen, C. Geisler, C. Agerbeck, J.P.H. Lauritsen, S.D. Gúdjonsdottir, L. Skov and C.M. Bonefeld

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12658

      • image
      • image
      • image
      • image

      What's already known about this topic?

      • The interleukin (IL)-23/Th17 axis is important for the pathogenesis of psoriasis. Innate lymphoid cells producing IL-17 and/or IL-22 are known to be involved in the pathogenesis of psoriasis.

      What does this study add?

      • An increased frequency of group 3 innate lymphoid cells is found in noninvolved psoriatic skin compared with healthy skin, which may indicate that these cells contribute to psoriasis development.
    7. Severe skin inflammation and filaggrin mutation similarly alter the skin barrier in patients with atopic dermatitis (pages 617–624)

      G. Mócsai, K. Gáspár, G. Nagy, B. Irinyi, A. Kapitány, T. Bíró, E. Gyimesi, B. Tóth, L. Maródi and A. Szegedi

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12743

      • image
      • image
      • image

      What's already known about this topic?

      • There is a strong genotype–phenotype link in patients with atopic dermatitis (AD) suffering from filaggrin (FLG) haploinsufficiency, but acquired FLG deficiency can also occur in patients with AD.
      • It is not known whether the clinical and laboratory characteristics of AD are influenced only by genetic or also by acquired FLG alterations.

      What does this study add?

      • Actual skin barrier impairment in patients with AD with severe skin inflammation is similar in patients with FLG wild-type and FLG mutant-type and correlates with the severity of skin inflammation (SCORing Atopic Dermatitis).
      • On the other hand the constant barrier deficiency in patients with FLG mutant-type results in an increased risk of allergic sensitization compared with patients with the wild-type.
    8. Assessment of the cutaneous immune response during Arthroderma benhamiae and A. vanbreuseghemii infection using an experimental mouse model (pages 625–633)

      L. Cambier, A. Weatherspoon, V. Defaweux, E.T. Bagut, M.P. Heinen, N. Antoine and B. Mignon

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12673

      • image
      • image
      • image
      • image
      • image
      • image

      What's already known about this topic?

      • Pathophysiology and immunology of dermatophytoses are still poorly understood.
      • Most in vivo studies have been performed using guinea pig-based models.
      • Several limitations, notably the lack of immunological tools for this animal species, render the development of a modern mouse model necessary for progress in the understanding of pathogenesis.

      What does this study add?

      • Using two peculiar fungal species isolated from humans, Arthroderma benhamiae and A. vanbreuseghemii, a new mouse model of dermatophytosis was developed.
      • Clinical, histopathological and immunohistological evaluations showed that this model is reproducible, fits with previous experimental infection models using guinea pigs and mimics superficial tinea in humans.
      • For the first time, the cutaneous cytokine response was assessed during a dermatophyte infection, showing that the role of the T-helper 17 pathway should now be considered.
    9. Diet and physical exercise in psoriasis: a randomized controlled trial (pages 634–642)

      L. Naldi, A. Conti, S. Cazzaniga, A. Patrizi, M. Pazzaglia, A. Lanzoni, L. Veneziano, G. Pellacani and the Psoriasis Emilia Romagna Study Group

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12735

      • image
      • image
      • image

      What's already known about this topic?

      • Obesity is a risk factor for psoriasis development in both adult and paediatric populations.
      • Psoriasis is associated with metabolic derangements, such as type II diabetes.
      • Obesity may reduce the response to systemic treatment.

      What does this study add?

      • This randomized controlled trial shows that an intervention combining diet restriction and promotion of physical exercise in overweight or obese patients with active psoriasis helps to reduce psoriasis severity beyond the effects of systemic treatment over a 20-week period.
      • The effect may be related to the weight loss alone, or to some indirect influence on patient compliance or other treatment components.
    10. Analysis of quantitative changes in hair growth during treatment with chemotherapy or tamoxifen in patients with breast cancer: a cohort study (pages 643–650)

      V. Kanti, R. Nuwayhid, J. Lindner, K. Hillmann, A. Stroux, N. Bangemann, A. Kleine-Tebbe, U. Blume-Peytavi and N. Garcia Bartels

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12716

      • image
      • image
      • image
      • image

      What's already known about this topic?

      • The frequency, severity and pattern of chemotherapy-induced alopecia vary, depending on the therapy regimen.

      What does this study add?

      • The course of hair loss shows variations, depending on the investigated area. The most prominent hair loss occurs after 6 weeks of chemotherapy.
      • Twelve weeks after cessation of chemotherapy, telogen hairs return to baseline, and anagen hairs and hair density recover, even to above baseline values in the occipital region.
      • No changes in anagen or telogen hairs, or hair density occur under tamoxifen therapy.
    11. Cutaneous allergy

      Molecular characterization of contact urticaria in patients with melon allergy (pages 651–656)

      M. Gandolfo-Cano, J. Bartra, E. González-Mancebo, F. Feo-Brito, E. Gómez, B. Bartolomé, E. Muñoz-García, A. Sanz Maroto, F. Vivanco, J. Cuesta-Herranz and C. Pastor-Vargas

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12701

      • image
      • image
      • image

      What's already known about this topic?

      • The relevance of contact allergy to plant-related food has recently emerged, and the number of patients reporting contact allergy to melon peel has increased strikingly; however, the allergens involved have not been studied.
      • Allergic reactions attributed to melon-pulp ingestion can be caused by contact with the peel of this fruit while eating it.

      What does this study add?

      • This study demonstrates that melon-peel lipid transfer protein is responsible for contact urticaria in patients sensitized to melon.
    12. Dermatological surgery and lasers

      Favre–Racouchot syndrome: a novel two-step treatment approach using the carbon dioxide laser (pages 657–660)

      S. Rai, V. Madan, P.J. August and J.E. Ferguson

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12742

      • image
      • image

      What's already known about this topic?

      • Favre–Racouchot syndrome is a difficult condition to treat effectively and, when treated, maintenance of treatment response remains a challenge.

      What does this study add?

      • We describe a novel two-step approach in the treatment of Favre–Racouchot syndrome.
      • Our method differs from other methods using CO2 laser as it uses silk touch resurfacing mode and manual extraction of comedones, which results in no apparent visual scarring.
      • This method achieves good cosmesis in one to two treatment sessions and is well tolerated by patients.
    13. Epidemiology and health services research

      Increased risk and pattern of secondary malignancies in patients with invasive extramammary Paget disease (pages 661–671)

      A. Karam and O. Dorigo

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12635

      What's already known about this topic?

      • The prognosis of patients with intraepithelial extramammary Paget disease (EMPD) is better compared with patients with an underlying malignancy.
      • The association of EMPD with distant malignancies as well as the high risk of recurrence raises the question of an elevated long-term risk of secondary malignancies.

      What does this study add?

      • Patients with EMPD are at increased risk of secondary malignancies, mainly colorectal and anal cancers.
      • The initial site of disease predicted the site of the secondary malignancies.
    14. You have free access to this content
      Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice (pages 672–680)

      K. Callis Duffin, H. Yeung, J. Takeshita, G.G. Krueger, A.D. Robertson, A.B. Troxel, D.B. Shin, A.S. Van Voorhees and J.M. Gelfand

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12745

      • image

      What's already known about this topic?

      • Patients' satisfaction with their treatments has important implications in medical decision making, treatment adherence and treatment success in real-world clinical practice.
      • Earlier research suggested dissatisfaction with current treatments among patients with moderate-to-severe psoriasis.

      What does this study add?

      • This study established benchmarks for comparing treatment satisfaction with current therapy among patients with moderate-to-severe psoriasis, using a validated instrument under real-world conditions.
      • Discernible differences were found in treatment satisfaction among treatments, particularly regarding treatment effectiveness and convenience.
    15. Paediatric dermatology

      Limb length discrepancy in cutis marmorata telangiectatica congenita: an audit of assessment and management in a multidisciplinary setting (pages 681–686)

      A. Memarzadeh, I. Pengas, S. Syed and D.M. Eastwood

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12700

      • image
      • image
      • image
      • image
      • image
      • image

      What's already known about this topic?

      • Cutis marmorata telangiectatica congenita (CMTC) is a rare lymphovascular malformation, diagnosed based on cutaneous manifestations.
      • It is associated with limb length discrepancy and asymmetry, but its exact extent and relationship to the site of the cutaneous manifestations have not been delineated.

      What does this study add?

      • We quantify the discrepancy seen in our CMTC population at a tertiary referral centre.
      • We propose a protocol to standardize the investigation and management of these patients.
    16. Photobiology

      You have free access to this content
      Altered global methylation and hydroxymethylation status in vulvar lichen sclerosus: further support for epigenetic mechanisms (pages 687–693)

      T. Gambichler, S. Terras, A. Kreuter and M. Skrygan

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12702

      • image
      • image

      What's already known about this topic?

      • Vulvar lichen sclerosus (VLS) is an autoimmune-mediated skin disorder that is frequently associated with cutaneous squamous cell carcinoma.
      • Ultraviolet (UV)A1 appears to be beneficial in lichen sclerosus but may also be associated with increased risk of photocarcinogenesis.

      What does this study add?

      • Altered expression of isocitrate dehydrogenases and aberrant global methylation and hydroxymethylation patterns were observed in VLS, indicating an epigenetic background for the pathogenesis of this condition.
      • Following long-term UVA1 phototherapy of VLS, normalization of 5-hydroxymethylation patterns and global DNA hypermethylation were observed.
      • The latter may raise concerns regarding photocarcinogenesis.
    17. Impact assessment of energy-efficient lighting in patients with lupus erythematosus: a pilot study (pages 694–698)

      L. Fenton, R. Dawe, S. Ibbotson, J. Ferguson, S. Silburn and H. Moseley

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12719

      • image
      • image
      • image

      What's already known about this topic?

      • Patients with lupus erythematosus (LE) can have abnormal cutaneous response to ultraviolet (UV) radiation.
      • Compact fluorescent lamps (CFLs) emit UV that can exacerbate certain photodermatoses.
      • UV-induced cutaneous response may lead to general disease progression including systemic activity.

      What does this study add?

      • Skin erythema is induced by repeated CFL exposure in healthy individuals and those with LE.
      • CFL-induced erythema is more persistent in individuals with LE.
      • Light-emitting diodes offer a safe alternative light source for individuals with LE, without the risk of UV.
    18. Therapeutics

      You have free access to this content
      Secondary cancers, comorbidities and mortality associated with nitrogen mustard therapy in patients with mycosis fungoides: a 30-year population-based cohort study (pages 699–704)

      L.M. Lindahl, M. Fenger-Grøn and L. Iversen

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12620

      What's already known about this topic?

      • Nitrogen mustard therapy is widely used in patients with mycosis fungoides (MF).
      • It remains controversial whether nitrogen mustard therapy is associated with secondary cancers and chronic pulmonary diseases in MF.

      What does this study add?

      • Nitrogen mustard therapy is not associated with increased risk of secondary cancers and comorbidities in MF.
      • Nitrogen mustard therapy does not influence mortality and causes of death in MF.
      • Nitrogen mustard is a safe therapy in patients with MF.
    19. You have full text access to this OnlineOpen article
      Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory (pages 705–715)

      K.B. Gordon, A.B. Kimball, D. Chau, H.N. Viswanathan, J. Li, D.A. Revicki, G. Kricorian and B.G. Ortmeier

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12636

      • image
      • image
      • image
      • image
      • image

      What's already known about this topic?

      • Psoriasis has a significant negative impact on health-related quality of life.

      What does this study add?

      • Brodalumab treatment provided statistically significant improvement in psoriasis symptoms and functional outcomes in patients with moderate-to-severe psoriasis.
      • These results support the further clinical development of brodalumab to treat patients with moderate-to-severe psoriasis.
    20. Concise communications

      Second nonmelanoma skin cancer in Spain: frequency and chronology (pages 716–719)

      J.J. Domínguez-Cruz, A. Nieto-García, J.J. Rios and D. Moreno-Ramirez

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12675

      • image
      • image

      What's already known about this topic?

      • Common guidelines recommend a 3–5-year follow-up for patients with nonmelanoma skin cancer (NMSC).
      • One of the aims is the early identification of a second or subsequent NMSC.

      What does this study add?

      • This study added to the knowledge about the risk and chronology of a second NMSC based on a large series of patients with NMSC (n = 926) followed up for a period of 10 years.
      • A second NMSC is a common event presenting in up to 22·6% of the patients, with the greatest risk corresponding to the first 5 years of follow-up.
    21. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas (pages 720–724)

      A. de Masson, P. Guitera, P. Brice, I. Moulonguet, F. Mouly, J.-D. Bouaziz, M. Battistella, I. Madelaine, J. Roux, C. Ram-Wolff, J.-M. Cayuela, H. Bachelez, A. Bensussan, L. Michel and M. Bagot

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12690

      • image
      • image

      What's already known about this topic?

      • Alemtuzumab has shown short-term efficacy in small numbers of patients with advanced primary cutaneous T-cell lymphomas.

      What does this study add?

      • Alemtuzumab may induce long-term remission (> 2 years) in patients with Sézary syndrome.
      • Alemtuzumab is poorly effective in nontransformed mycosis fungoides and transformed CTCL.
    22. Tolerance to COX-2 inhibitors in children with hypersensitivity to nonsteroidal anti-inflammatory drugs (pages 725–729)

      J.L. Corzo, M.A. Zambonino, C. Muñoz, C. Mayorga, G. Requena, A. Urda, C. Gallego, M. Blanca and M.J. Torres

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12674

      What's already known about this topic?

      • In children with hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs), different nonchemically related NSAIDs as well as paracetamol can induce the reaction, with paracetamol thought to be the only safe alternative.
      • However, in up to 25% of cases paracetamol can also induce a reaction, leaving the patients with no possibility of anti-inflammatory treatment.
      • There is no information about tolerance to other alternatives such as COX-2 inhibitors.

      What does this study add?

      • We have confirmed in a retrospective analysis that all children with confirmed NSAID hypersensitivity and older than 8 years of age tolerated etoricoxib administration, with 5% of the children reacting with meloxicam.
      • To our knowledge this is the first study undertaken in children that evaluates the tolerance to COX-2 inhibitors.
    23. Primary cutaneous amyloidosis of the glans penis. Two case reports and a review of the literature (pages 730–734)

      E.E. Merika, M.Ι. Darling, P. Craig, M. Paul, N. Francis, H. Lachmann, W. Porter and C.B. Bunker

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12682

      • image
      • image
      • image
      • image

      What's already known about this topic?

      • Primary cutaneous amyloidosis of the penis is a rare entity.
      • Nodular cutaneous amyloid is associated with systemic disease and up to 10% cases with associated paraproteinaemia progress to systemic disease.

      What does this study add?

      • True penile-limited cutaneous amyloidosis is highly associated with nodular amyloidosis.
      • Primary cutaneous penile amyloidosis has a low incidence of systemic progression.
  8. Correspondence

    1. Top of page
    2. Editor's Choice
    3. Editorials
    4. Commentaries
    5. Putting papers into practice
    6. Review articles
    7. Meeting report
    8. Original articles
    9. Correspondence
    10. News and Notices
    11. Plain language summary
    12. Abstract
    1. Distinctive immunoglobulin VH gene features of cutaneous marginal zone lymphomas in Asian cases (pages 735–737)

      Y. Ge, H. Takino, F. Sato, S. Yamada, A. Masaki, Y. Fujiyoshi, H. Hattori, A. Morita, T-T. Kuo and H. Inagaki

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12614

    2. In vivo determination of epidermal thickness using high-definition optical coherence tomography (pages 737–739)

      T. Gambichler, K. Valavanis, I. Plura, D. Georgas, P. Kampilafkos and M. Stücker

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12668

      • image
      • image
    3. Travel-acquired subcutaneous Sparganum proliferum infection diagnosed by molecular methods (pages 741–743)

      F. Schauer, S. Poppert, K. Technau-Hafsi, M. Mockenhaupt, B. Muntau, G. Häcker, D. Tappe and T. Jakob

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12679

      • image
    4. Brunsting–Perry-type cicatricial pemphigoid with IgG autoantibodies to LAD-1 (pages 743–745)

      P. García-Martín, J. Fraga, T. Hashimoto and A. García-Diez

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12677

      • image
      • image
    5. Ulcerative keratitis in psoriasis: a rare variant of psoriatic ocular inflammatory disease (pages 746–748)

      V.G. Herbert, B. Lögering, V. von Gruben, F. Filev, M. Klemm and K. Reich

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12686

      • image
      • image
      • image
    6. Rhinophyma on the web (pages 750–751)

      A. Shah, R. Lakhani and J. Panesar

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12696

      • image
    7. Noninvasive, in vivo assessment of oral squamous cell carcinoma (pages 754–756)

      M. Agozzino, P. Bhasne, C. Franceschini, G. Vincenza, C. Catricalà and M. Ardigò

      Article first published online: 12 MAR 2014 | DOI: 10.1111/bjd.12728

      • image
      • image
  9. News and Notices

    1. Top of page
    2. Editor's Choice
    3. Editorials
    4. Commentaries
    5. Putting papers into practice
    6. Review articles
    7. Meeting report
    8. Original articles
    9. Correspondence
    10. News and Notices
    11. Plain language summary
    12. Abstract
  10. Plain language summary

    1. Top of page
    2. Editor's Choice
    3. Editorials
    4. Commentaries
    5. Putting papers into practice
    6. Review articles
    7. Meeting report
    8. Original articles
    9. Correspondence
    10. News and Notices
    11. Plain language summary
    12. Abstract
    1. You have free access to this content
  11. Abstract

    1. Top of page
    2. Editor's Choice
    3. Editorials
    4. Commentaries
    5. Putting papers into practice
    6. Review articles
    7. Meeting report
    8. Original articles
    9. Correspondence
    10. News and Notices
    11. Plain language summary
    12. Abstract

SEARCH

SEARCH BY CITATION